# Antimicrobial Stewardship in Food Animals: Withdrawal Times and Residue Avoidance


## Key Takeaways

- Withdrawal times (WDTs) are legally mandated intervals between the last veterinary drug administration and the safe harvest of edible animal products, ensuring drug residues remain below established tolerance limits. These limits are determined by toxicological assessments and human consumption patterns, with regulatory bodies like the WOAH setting international standards.
- Residue depletion follows pharmacokinetic principles, with elimination half-life, tissue binding, and metabolism dictating clearance rates; kidney and liver are common sites of persistent residues due to their roles in excretion and metabolism, influencing tissue-specific tolerances and WDTs. Physiologically Based Pharmacokinetic (PBPK) models offer advanced prediction of residue depletion, enabling more precise WDT estimation, particularly for extralabel use.
- Extralabel drug use (ELDU) necessitates veterinarian-determined extended withdrawal intervals, as deviations from label indications (dose, route, duration, species) alter residue depletion kinetics. Population PBPK modeling provides a scientifically defensible method for calculating these extended WDTs, while in its absence, consultation with resources like FARAD and conservative extrapolation from label data are critical.
- Species and production system variations significantly impact residue depletion; for instance, ruminants present unique challenges due to rumen metabolism, and dairy cattle require separate milk discard times, often longer than meat WDTs due to milk testing sensitivity and continuous harvest. By-products like poultry claws can also harbor persistent residues, necessitating consideration beyond primary edible tissues.
- Antimicrobial stewardship and residue avoidance are integrated responsibilities; judicious use principles inherently reduce residue risk, while the practical constraint of WDTs influences antimicrobial selection. Knowledge gaps among users, particularly in informal drug distribution channels, contribute to residue violations, underscoring the need for comprehensive education and regulatory oversight across the entire supply chain.
- Accurate WDT calculation requires a stepwise assessment, beginning with label confirmation, identifying all deviations from label conditions, applying safety factors (e.g., dose ratio multipliers), identifying the target tissue, and adjusting for patient factors like renal or hepatic impairment. Meticulous documentation of the drug, dose, route, duration, rationale for extension, and final withdrawal dates in the medical record is a critical legal and stewardship obligation.

---

Withdrawal times are the interval between the last administration of a veterinary drug and the point at which edible products from the treated animal can be safely harvested for human consumption. These intervals exist to ensure that drug residues in meat, milk, eggs, and edible tissues fall below established tolerance limits before entering the food supply. For the food animal practitioner, accurate withdrawal time determination is a legal obligation, a food safety safeguard, and an integral component of antimicrobial stewardship. This article addresses the scientific basis of withdrawal times, the factors that influence residue depletion, the legal frameworks governing residue tolerances, and the practical strategies veterinarians can apply to prevent violative residues in food animal practice.

The clinical question this reference answers is direct: how does a practitioner determine an appropriate withdrawal interval when using an antimicrobial in a food animal, and what systems can be implemented to prevent residue violations? The article serves veterinarians in mixed or food animal practice, regulatory veterinarians, and veterinary students preparing for clinical work with production species. It covers the pharmacology of residue depletion, the regulatory architecture that defines tolerances and safe levels, the consequences of withdrawal time violations, and the stewardship principles that connect judicious antimicrobial use to residue avoidance. Specific drug dosages are excluded, the focus is on the decision framework and the science that underpins it.

## At a Glance

| Parameter | Clinical Relevance |
|---|---|
| Tolerance | Maximum legally permitted drug concentration in a specific edible tissue, established by regulatory authorities |
| Marker residue | The parent drug or metabolite monitored to demonstrate compliance with the tolerance |
| Withdrawal time | Interval from last drug administration to when edible products are safe for consumption |
| Extralabel use | Use of an approved drug in a manner not specified on the label, requiring withdrawal interval extension |
| Residue depletion | The decline of drug concentration in tissues over time, governed by pharmacokinetic principles |
| Violative residue | A residue concentration exceeding the established tolerance in an edible product |
| Milk discard time | The specific withdrawal interval applied to milk, often longer than meat withdrawal due to milk testing sensitivity |
| Population-based estimation | Withdrawal times are calculated for the 99th percentile of the treated population, not the average animal |

## Pharmacokinetic Basis of Residue Depletion

Residue depletion follows the same pharmacokinetic principles that govern drug disposition in any patient. After administration, an antimicrobial distributes from plasma into tissues, then eliminates through metabolism and excretion. The rate of elimination determines how quickly tissue concentrations fall below the tolerance threshold. Drugs with short elimination half-lives clear rapidly, while those with long half-lives or extensive tissue binding persist for extended periods. Lipid-soluble drugs accumulate in adipose tissue, while certain drugs bind to protein in the kidney or liver, creating tissue-specific residue patterns that influence which matrix must be monitored.

The kidney and liver are the most common sites of persistent residues because of their roles in drug excretion and metabolism. Muscle and fat typically clear more rapidly. This tissue-specific distribution explains why regulatory tolerances differ by tissue and why the withdrawal time is set to ensure that the slowest-clearing edible tissue falls below its tolerance. The practitioner must know which tissue is the target for residue monitoring in the relevant regulatory jurisdiction, because this determines the practical withdrawal interval.

Physiologically based pharmacokinetic (PBPK) models have advanced the ability to predict residue depletion across species and dosing scenarios. A PBPK model developed for penicillin G in swine and cattle successfully predicted drug concentrations in liver, muscle, and kidney, including data not used in model calibration. The model was applied to estimate extended withdrawal intervals for extralabel use at 5 and 10 times the label dose, using Monte Carlo sampling to predict the time needed for tissue concentrations to fall below established tolerances for the 99th percentile of the population. This approach demonstrates that residue prediction can be refined beyond the empirical withdrawal times printed on labels, particularly when extralabel dosing is necessary.

## Regulatory Framework for Residue Tolerances

Regulatory authorities in each jurisdiction establish the tolerance for each approved drug in each edible tissue. The tolerance represents the maximum concentration legally permitted, and it is derived from toxicological assessment of the drug's safety profile, including acceptable daily intake calculations and consideration of the human consumption patterns for each tissue. The World Organization for Animal Health publishes international standards for veterinary drug residues in its Terrestrial Animal Health Code, which provides a reference framework for national regulatory programs.

The approved label for each drug product includes the withdrawal time established during the approval process. This label withdrawal time applies only when the drug is used exactly as labeled: same species, same indication, same dose, same route, and same duration. Any deviation from the label constitutes extralabel use, which triggers a requirement for the prescribing veterinarian to establish an extended withdrawal interval. The United States Food and Drug Administration Center for Veterinary Medicine provides regulatory information on approved animal drugs, labeling requirements, and extralabel use policy, and the American Veterinary Medical Association offers professional guidance on judicious antimicrobial use that incorporates residue avoidance as a core stewardship principle.

## Extralabel Use and Withdrawal Interval Extension

Extralabel drug use is common in food animal practice because approved indications do not cover every clinical scenario. When a veterinarian prescribes an antimicrobial extralabel, the responsibility for establishing a safe withdrawal interval shifts from the drug manufacturer to the prescribing veterinarian. The default approach is to extend the label withdrawal time by a factor that accounts for the increased dose, altered route, or different species. For example, doubling the label dose typically requires more than doubling the withdrawal time because residue depletion is not linear with dose.

Population physiologically based pharmacokinetic modeling offers a more precise method for estimating extended withdrawal intervals. The penicillin G model referenced above predicted withdrawal times for extralabel doses at the 99th percentile of the population, providing a defensible basis for clinical decisions. When such models are not available for a specific drug and species combination, the practitioner must rely on published residue depletion studies, consultation with the Food Animal Residue Avoidance Databank or equivalent national programs, and conservative extrapolation from label data.

## Species and Production System Considerations

Residue depletion kinetics differ between species, and the practitioner must account for these differences when establishing withdrawal intervals. Ruminants present particular challenges because of the complexity of drug distribution into the gastrointestinal tract and the potential for prolonged elimination. Dairy cattle require separate consideration for milk, because the milk discard time is often longer than the meat withdrawal time due to the sensitivity of milk testing methods and the continuous nature of milk harvest.

Poultry production introduces additional matrices that may enter the food chain indirectly. A study of oxytetracycline depletion in broiler chicken claws demonstrated that residues persist in this by-product for extended periods, with withdrawal times of 39 days for oxytetracycline and 54 days for its metabolite 4-epi-oxytetracycline established at 95% confidence. Claws are processed into meals for animal feeding, which means residues can cycle back into the food chain through a secondary route. This finding illustrates that residue avoidance extends beyond the primary edible tissues to include by-products that may not be immediately obvious to the practitioner.

## Stewardship and Residue Prevention as Integrated Practice

Antimicrobial stewardship and residue avoidance are complementary obligations. Judicious use principles emphasize selecting the right drug, at the right dose, for the right duration, and this discipline naturally reduces the risk of violative residues. Conversely, the need to observe withdrawal times creates a practical constraint on antimicrobial selection, because a long withdrawal interval may be economically or logistically unacceptable in a given production system. The practitioner must balance therapeutic efficacy, stewardship principles, and withdrawal time practicality when designing treatment protocols.

Knowledge gaps among antimicrobial users contribute to residue violations. A cross-sectional survey of antimicrobial users and providers in western Kenya found that approximately 40% of veterinary antimicrobials were sold without a prescription and that more than half of agrovet staff did not hold nationally mandated qualifications to advise on or sell veterinary antimicrobials. Similar patterns of informal antimicrobial access and incomplete withdrawal time knowledge have been documented in smallholder dairy systems in Tanzania, where oxytetracycline residues were detected in raw milk. These findings underscore that residue avoidance depends on the entire chain of antimicrobial distribution and use, from regulatory oversight through prescribing practice to on-farm compliance.

## Withdrawal Time Calculation: A Practical Framework

The veterinarian's responsibility extends beyond prescribing to verifying that the chosen drug, dose, route, and withdrawal interval align with the legal label or with a defensible extralabel extension. The calculation begins with the label withdrawal period for the specific product, species, and route of administration. When the use is exactly as labelled, the withdrawal time printed on the product label governs. When any parameter deviates, the veterinarian must derive an extended interval.

### Stepwise Assessment Sequence

The first step is to confirm the approved label withdrawal period for the exact product, species, and indication. This information appears on the product label and in the [FDA Center for Veterinary Medicine animal drug information](https://www.fda.gov/animal-veterinary). The second step is to identify every deviation from label conditions: higher dose, different route, longer duration, off-label species, or concurrent disease that may alter clearance. Each deviation independently extends the required interval.

The third step is to apply a safety factor. For extralabel use, the Food Animal Residue Avoidance Databank (FARAD) recommends extending the label withdrawal period by a factor that accounts for the magnitude of the dose increase and the tissue in which residues persist longest. A commonly used approach is to multiply the label withdrawal time by a factor proportional to the dose ratio, then add additional days for safety. For penicillin G, population physiologically based pharmacokinetic modeling has shown that extralabel doses of 5 and 10 times the label dose require substantially extended withdrawal intervals to ensure that the 99th percentile of treated animals falls below established tolerances in edible tissues [development and application of a population physiologically based pharmacokinetic model for penicillin G in swine and cattle](https://pubmed.ncbi.nlm.nih.gov/28627373/).

The fourth step is to identify the target tissue. The marker tissue, usually liver or kidney, is the tissue in which residues persist longest and the tissue that regulatory testing samples. For penicillin G, the kidney is the target tissue in both swine and cattle. For oxytetracycline, residues persist in bone and in claws of poultry, a by-product that can enter animal feed [residue depletion of oxytetracycline and 4-epi-oxytetracycline in broiler chicken claws](https://pubmed.ncbi.nlm.nih.gov/27879173/). The veterinarian must consider also the edible muscle but also all tissues and by-products that may enter the human food chain directly or indirectly.

### Decision Points That Change the Calculation

The correct withdrawal interval changes with species. Ruminants with functional rumens metabolise some drugs differently than monogastrics, and the same drug may have different label withdrawal periods for cattle, swine, sheep, and poultry. The interval also changes with the production system. Dairy cattle have separate withdrawal times for milk and for meat, and the milk withdrawal time is often the limiting factor. In laying hens, eggs are the limiting matrix. In veal calves and young animals, immature hepatic and renal function may slow drug elimination, requiring longer intervals than the label states for mature animals.

Patient status changes the calculation. Dehydration, fever, hepatic disease, and renal disease all alter drug clearance. A dehydrated animal with reduced renal perfusion will clear penalty excreted drugs more slowly. The veterinarian should extend the withdrawal interval when any condition that impairs elimination is present. The [MSD Veterinary Manual professional edition](https://www.msdvetmanual.com/) provides species-specific pharmacology guidance that supports these clinical judgments.

### Documentation and Record Keeping

The withdrawal time calculation must be documented in the medical record before the drug is administered. The record should include the drug, dose, route, duration, the label withdrawal period, the basis for any extension, and the final withdrawal date for each relevant matrix. For extralabel use, the record should also document the rationale for the extralabel decision and the source of the withdrawal interval estimate. The [AVMA antimicrobial use and stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) emphasize that documentation is a core stewardship responsibility.

### Monitoring and Verification

Verification that residues have depleted to below tolerance requires either adherence to a conservatively calculated withdrawal interval or actual residue testing. On-farm residue screening tests are available for some drug classes, but their sensitivity and specificity vary. A negative screening test does not guarantee that residues are below the regulatory tolerance, particularly for drugs with low tolerances or for metabolites not detected by the screening method. Confirmatory testing by a laboratory using chromatographic methods is required when a screening test is positive or when regulatory action is anticipated.

### A Checklist for Calculating and Documenting Withdrawal Times

| Step | Action | Documentation Required |
|------|--------|------------------------|
| 1 | Confirm the label withdrawal period for the exact product, species, and route | Product label, drug reference |
| 2 | Identify all deviations from label conditions | Dose, route, duration, species, patient status |
| 3 | Apply a safety factor for each deviation | FARAD or PBPK-derived extension, dose ratio |
| 4 | Identify the target tissue and limiting matrix | Marker tissue, milk, eggs, by-products |
| 5 | Adjust for patient factors that alter clearance | Renal, hepatic, hydration status |
| 6 | Calculate the final withdrawal date for each matrix | Date of last dose plus extended interval |
| 7 | Document the calculation in the medical record | Drug, dose, route, rationale, final dates |
| 8 | Communicate the withdrawal dates to the producer in writing | Written instructions, signed acknowledgement |
| 9 | Verify compliance at slaughter or milk pickup | Treatment records, residue screening if indicated |

The veterinarian should provide the producer with a written record of withdrawal dates for each treated animal or group. This record should travel with the animals if they are sold or moved to another premises. The [WOAH terrestrial animal health code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) addresses the responsibilities of veterinary authorities and producers in ensuring that treated animals do not enter the food chain before residues have depleted.

### Common Failure Modes

The most common failure is reliance on a single withdrawal time for all animals in a group when individual animals received different doses or were treated on different days. Group-level withdrawal dates must be based on the highest dose and the latest treatment date in the group. A second failure is ignoring the milk withdrawal time when treating dry cows that may calve early. A third failure is assuming that a withdrawal time for one route applies to another route, for example, topical or intramammary preparations may have different depletion profiles than systemic injections. A fourth failure is neglecting to extend the withdrawal interval when renal or hepatic disease is present, particularly in older animals.

## Recognized Complications and Early Detection

Violative residues are seldom the result of a single catastrophic error. They accumulate from small miscalculations in dose, duration, or withdrawal timing that compound across a treatment course. The most frequently recognized failure mode is the assumption that label withdrawal times apply to extralabel dose rates. When penicillin G is administered at multiples of the label dose, tissue concentrations decline along a different curve, and the time to reach tolerance may extend substantially beyond the labelled interval. Population physiologically based pharmacokinetic modeling has demonstrated that extended withdrawal intervals are required for extralabel penicillin G use in swine and cattle, with variability across the population wide enough that a single fixed extension cannot be assumed safe for every animal ([population PBPK model for penicillin G in swine and cattle](https://pubmed.ncbi.nlm.nih.gov/28627373/)).

A second failure mode involves sampling the wrong tissue or matrix. Residue depletion is tissue-specific, and kidney and liver typically retain drugs longer than muscle. In poultry, claws and other by-products may carry oxytetracycline residues well beyond the withdrawal interval established for muscle, with depletion studies showing measurable concentrations in claws for weeks after treatment ([residue depletion of oxytetracycline in broiler claws](https://pubmed.ncbi.nlm.nih.gov/27879173/)). Clinicians who verify clearance only in muscle may miss persistent residues in tissues that enter the food chain through rendering or pet food channels.

A third complication is the interaction between disease status and drug disposition. Hepatic or renal compromise, dehydration, and concurrent inflammation alter clearance kinetics. The withdrawal interval that is adequate for a healthy cohort may be insufficient for severely affected animals. Early detection depends on maintaining a treatment log that records also the drug and dose but also the clinical condition of each animal, so that animals with suspected altered clearance can be held longer before slaughter.

## Common Errors and Corrective Actions

Less experienced clinicians frequently confuse withdrawal time with milk discard time, or assume that a single withdrawal period applies across all formulations of the same drug. Oxytetracycline products vary in vehicle, salt form, and route, and each formulation carries its own depletion profile. The corrective action is to verify the specific product label and, for extralabel use, to consult a residue avoidance resource before treatment begins.

A second recurring error is the failure to account for the last animal treated. When a group is treated over several days, the withdrawal clock starts at the final treatment, not the first. Clinicians who calculate from the first dose may release animals prematurely. The discriminating check is to review the treatment log for the date of the last injection or the last medicated feed delivery.

A third error is the assumption that regulatory oversight is uniform across regions. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) and the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) set frameworks that individual countries implement with local variation. A withdrawal interval that is compliant in one jurisdiction may be violative in another, particularly for export production.

## Limitations of the Evidence

The evidence base for withdrawal intervals is strongest for common drugs in conventional production systems and weakest for extralabel combinations, novel formulations, and non-standard matrices. Much of the published depletion data derives from healthy, uniform populations, and extrapolation to diseased or stressed animals carries genuine uncertainty. Expert opinion differs on how much additional margin is prudent when the evidence base is thin. Some authorities advocate a fixed percentage extension for all extralabel use, while others recommend case-by-case calculation using pharmacokinetic modeling. Both positions are defensible, neither is universally correct.

## Escalation and Referral

Referral to a veterinary pharmacologist or a diagnostic laboratory is warranted when residue risk is high and the margin for error is small, such as in animals destined for export or in herds with a prior residue violation. Laboratory testing for tissue or milk residues should be considered whenever clinical judgment suggests that the calculated withdrawal interval may be inadequate. Regulatory reporting is required when a violative residue is confirmed or strongly suspected, and the responsible veterinarian should contact the relevant authority promptly. Consultation with a specialist is also appropriate when treating conditions with limited residue data, such as digital dermatitis, where topical and systemic therapies are used in combinations that have not been systematically evaluated for residue depletion ([bovine digital dermatitis current concepts](https://pubmed.ncbi.nlm.nih.gov/27061657/)).

## Troubleshooting Table

| Observation | Likely Cause | Discriminating Check |
| --- | --- | --- |
| Residue detected after labelled withdrawal | Extralabel dose or duration used | Compare treatment record to label, recalculate from last dose |
| Residue in by-product but not muscle | Tissue-specific depletion | Test kidney, liver, or claws separately |
| Milk residue after meat withdrawal met | Different withdrawal periods for milk and meat | Verify both intervals on the product label |
| Group released early | Withdrawal calculated from first treatment | Confirm date of last treatment in the log |
| Regional regulatory conflict | Jurisdictional variation in tolerances | Check destination market requirements before shipment |

## Frequently Asked Questions

### How Do I Handle Withdrawal Time Decisions When the Label Withdrawal Period Is Unknown or Unavailable?

When label information is missing, consult the Food Animal Residue Avoidance Databank (FARAD) or your national residue avoidance program before treating. For extralabel use, regulatory frameworks require an extended withdrawal interval, but the appropriate extension depends on the drug's pharmacokinetics and the species. Population physiologically based pharmacokinetic models can predict tissue residue depletion for drugs such as penicillin G in swine and cattle, providing a science-based approach to estimating withdrawal intervals when label data do not apply. Document your reasoning, including the source consulted and the basis for the chosen interval. If no reliable estimate can be made, consider an alternative approved drug with a known withdrawal period. Current formulary references and regulatory guidance must be consulted for each case.

### What Should I Do When a Client Cannot Afford the Required Holding Period for Milk or Meat?

Financial pressure does not justify releasing product with violative residues. Discuss the economic consequences of a residue violation, including milk tank rejection, carcass condemnation, and regulatory penalties, which typically far exceed the cost of holding product. Explore management options such as segregating treated animals, extending the lactation period for non-saleable milk, or using a shorter withdrawal drug when clinically appropriate. In some regions, insurance or cooperative programs offset losses from mandatory withdrawal periods. If the client refuses to comply, decline to treat and document the conversation. The veterinarian retains legal responsibility for withdrawal recommendations, and professional guidance on judicious antimicrobial use supports refusing participation in practices that create residue risks.

### How Do Withdrawal Times Differ Between Dairy and Beef Cattle for the Same Drug?

Dairy and beef cattle differ in residue depletion kinetics because of physiological factors including lactation, body condition, and metabolic rate. Milk withdrawal periods are established separately from meat withdrawal periods, and the longer of the two governs when the animal can enter the food chain. For lactating dairy cows, extralabel drug use is heavily restricted in many jurisdictions because of the risk of violative milk residues. Beef cattle withdrawal estimates often assume a specific injection site and route, and subcutaneous administration may deplete faster than intramuscular injection. Population pharmacokinetic models for drugs such as penicillin G account for species-specific physiology and can estimate tissue concentrations in both swine and cattle. Always verify the label withdrawal period for the specific species, production class, and route of administration.

### What Records Must I Keep to Defend a Withdrawal Time Decision in an Audit or Investigation?

Maintain a complete treatment record that includes the animal identification, drug name, lot number, dose, route, site of administration, date and time of treatment, and the calculated withdrawal period for meat and milk. Record the basis for the withdrawal calculation, including the label reference, FARAD consultation, or pharmacokinetic model used. Note any extralabel use justification and the client's informed consent. Keep these records for at least the period required by your jurisdiction, which may extend beyond the animal's slaughter date. Regulatory bodies and professional organizations provide practice resources that outline documentation expectations. In an audit, contemporaneous records that show a systematic approach to withdrawal calculation are substantially more defensible than retrospective explanations.

### How Do I Explain Withdrawal Times to a Producer Who Views Them as an Administrative Burden?

Frame withdrawal times as a food safety control point that protects consumer health and market access. Explain that violative residues can trigger regulatory action, loss of buyer contracts, and reputational damage that affects the entire operation. Use concrete examples from residue surveillance studies, such as oxytetracycline residues detected in milk from smallholder dairy systems where withdrawal advice was inconsistent. Emphasize that withdrawal periods are derived from residue depletion studies and are set to ensure that tissue concentrations fall below established tolerances for the vast majority of treated animals. Position the withdrawal period as part of the treatment plan, not an afterthought, and integrate it into the herd health calendar so that treated animals are identified and tracked systematically.

### What Are the Consequences of a Violative Residue, and How Should I Respond If One Occurs?

Consequences include carcass or milk condemnation, regulatory penalties, loss of export certification, and legal liability for the veterinarian and producer. If a violative residue is suspected or confirmed, notify the relevant regulatory authority according to your jurisdiction's requirements. Conduct a root cause analysis to identify whether the failure was due to an incorrect withdrawal calculation, misidentification of the treated animal, or failure to communicate the withdrawal period to farm staff. Review the treatment records and the drug's label information to determine whether the error was systematic or isolated. Implement corrective actions such as improved animal identification, a written treatment protocol, and staff training. Professional guidance on antimicrobial stewardship supports using such incidents as learning opportunities to strengthen residue prevention practices.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Development and application of a population physiologically based pharmacokinetic model for penicillin G in swine and cattle for food safety assessment.](https://pubmed.ncbi.nlm.nih.gov/28627373/). 2017.
- [Bovine digital dermatitis: Current concepts from laboratory to farm.](https://pubmed.ncbi.nlm.nih.gov/27061657/). 2016.
- [Survey of Smallholder Dairy Cattle Farming System and Antibiotic Residues in Raw Cow's Milk in Bagamoyo District, Tanzania.](https://pubmed.ncbi.nlm.nih.gov/42525488/). 2026.
- [A Cross-Sectional Survey of the Knowledge, Attitudes, and Practices of Antimicrobial Users and Providers in an Area of High-Density Livestock-Human Population in Western Kenya.](https://pubmed.ncbi.nlm.nih.gov/34621809/). 2021.
- [Residue depletion of oxytetracycline (OTC) and 4-epi-oxytetracycline (4-epi-OTC) in broiler chicken's claws by liquid chromatography-tandem mass spectrometry (LC-MS/MS).](https://pubmed.ncbi.nlm.nih.gov/27879173/). 2017.
- [A Cross-Sectional Survey of the Knowledge, Attitudes & Practices of Antimicrobial Users and Providers in an Area of High-Density Livestock-Human Population in Western Kenya](https://doi.org/10.1101/2021.06.23.21259378). 2021.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Antimicrobial Stewardship in Food Animals: Principles and Practical Application](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-food-animals-principles-practical-application)
- [Antimicrobial Stewardship in Equine Practice: Challenges and Solutions](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-equine-practice-challenges-solutions)
- [Antimicrobial Stewardship in Respiratory Infections of Dogs and Cats](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-respiratory-infections-dogs-cats)
- [Antimicrobial Stewardship in Small Animal Practice: Implementing a Program](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-small-animal-practice-implementing-program)
- [Antimicrobial Stewardship in Canine Diarrhea: When Antibiotics Are Not the Answer](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-diarrhea)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.